Center for Learning and Health
Baltimore, Maryland, 21224, United States
NCT Number: NCT02487745
The purpose of this clinical trial is to evaluate the effectiveness and economic benefits of a Wage Supplement Model of arranging long-term exposure to employment-based abstinence reinforcement.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Baltimore, Maryland, 21224, United States
Drug addiction is as a chronic relapsing disorder. High magnitude and long-duration voucher-based abstinence reinforcement is one of the most effective treatments for drug addiction and can maintain drug abstinence over extended periods of time, but practical methods of implementing these interventions are needed. Workplaces could be ideal and practical vehicles for arranging and maintaining abstinence reinforcement over long time periods. The investigator's research on a model Therapeutic Workplace has shown that employment-based abstinence reinforcement, in which participants must provide drug-free urine samples to maintain maximum pay, can maintain drug abstinence. Now what is needed is the development of effective and economically sound methods to arrange long-term exposure to employment-based abstinence reinforcement. The present study will evaluate the effectiveness and economic benefits of a Wage Supplement Model of arranging long-term exposure to employment-based abstinence reinforcement. Under this model, successful Therapeutic Workplace participants are offered abstinence-contingent wage supplements if they obtain and maintain competitive employment. Governments have used wage supplements effectively to increase employment in welfare recipients. The Wage Supplement Model harnesses the power of wage supplements to promote employment, while simultaneously using the wage supplements to reinforce drug abstinence. The intervention will combine the Therapeutic Workplace, Individual Placement and Support (IPS) supported employment, and abstinence-contingent wage supplements. IPS is a supported employment intervention that has been proven effective in promoting employment in adults with severe mental illness. Under this model, participants will be exposed to the Therapeutic Workplace to initiate drug abstinence and establish job skills. To promote employment and prevent relapse to drug use, participants will receive IPS Plus Abstinence-Contingent Wage Supplements. A randomized trial will evaluate the effectiveness and economic benefits of the Abstinence-Contingent Wage Supplement Model in promoting employment and sustaining abstinence in heroin users. Participants will be enrolled in the Therapeutic Workplace for 3 months and then randomly assigned to an IPS Only group or an IPS Plus Abstinence-Contingent Wage Supplement group for one year. IPS Only participants will receive the IPS intervention. IPS Plus Abstinence-Contingent Wage Supplement participants will receive the IPS intervention and abstinence-contingent wage supplements. Drug use while participants are employed in community jobs will be monitored by American Substance Abuse Professionals, Inc. (ASAP®), a leading provider of workplace substance abuse services in the U.S. This novel intervention could be an effective and economically sound way to promote long-term abstinence and employment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Before obtaining competitive employment, participants will be able to earn wage supplements for attending two individual placement and support (IPS) supported employment sessions per week, and for completing specific tasks prescribed by IPS including developing a worker profile, applying for appropriate jobs, and completing job interviews. Once a participant becomes employed, participants will be able to earn up to $5 per hour for every hour worked in a competitive job up to 40 hours per week verified by pay stubs. To maintain long-term drug abstinence, participants will be required to provide urine samples to earn the maximum in wage supplements.
Individual Placement and Support (IPS) supported employment involves rapid job search, promotes competitive employment, considers the participant's preferences, and provides job supports and benefits counseling. An employment specialist will establish relationships will potential employers and work with participants to identify potential jobs, prepare applications, and to apply for positions.
Time frame: 1 year
(# opiate- and cocaine-negative urine samples/divided by possible #) x 100
Time frame: 1 year
(# participants employed /divided by total # of participants) x 100
Time frame: 1 year
(# participants reporting injecting drugs /divided by total # of participants) x 100
Time frame: 1 year
(# participants reporting trading unprotected sex for drugs or money/divided by total # of participants) x 100
Time frame: 1 year
(# participants reporting sharing injection equip/divided by total # of participants) x 100
Time frame: 1 year
(# participants with incomes below federal poverty level/divided by total # of participants) x 100
Time frame: Year 2
This will be measured after the intervention ends
Time frame: Year 2
This will be measured after the intervention ends
Time frame: Year 2
This will be measured after the intervention ends
Time frame: Year 2
This will be measured after the intervention ends
Time frame: Year 2
This will be measured after the intervention ends
Time frame: 2 years
The Cost-Benefit Analysis (CBA) will compare the monetized benefits relative to costs
Johns Hopkins University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03502525
Chemically-Induced Disorders, Mental Disorders
New York, United States
View Trial DetailsNCT04556552
Chemically-Induced Disorders, Mental Disorders
Atlanta, Georgia, United States
View Trial DetailsNCT02774954
Amphetamine Dependence, Amphetamine-Related Disorders
Los Angeles, California, United States
View Trial DetailsNCT02796027
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
New York, United States
View Trial Details